During 2023, Alaska reported **** new cases of tuberculosis per 100,000 population, the highest rate of any state. This statistic shows the number of new cases of tuberculosis per 100,000 population in the United States in 2023, by state.

Tuberculosis in the United States

New cases of tuberculosis (TB) in the United States have decreased steadily since the *****, mostly due to the discovery and use of antibiotics as an effective treatment for this contagious lung disease caused by bacteria. Other factors contributing to the decline include the ongoing work of local and national programs to detect, treat, and prevent TB disease and transmission, such as reporting and surveillance systems, as well as public health strategies. Unfortunately, TB continues to be one of the deadliest communicable diseases worldwide, as many developing countries still lack the health systems and resources needed to effectively reduce the TB burden.

Risk populations in the U.S.

Tuberculosis often adversely affects groups of people who have experienced health obstacles throughout history, often based on race or ethnicity. In the U.S., cases of TB continue to be disproportionately distributed among various ethnicities: in 2022, over one third of TB cases were among Asians and another third among the Hispanic population. Furthermore, in 2022, higher rates of TB cases were reported among Native Hawaiians or Pacific Islanders and American or Alaskan Natives. Other at-risk populations include non-U.S. born persons of various races or ethnicities, as new TB cases are often found during immigrant medical examinations.

United States US: Incidence of Tuberculosis: per 100,000 People data was reported at 3.100 Ratio in 2016. This records a decrease from the previous number of 3.300 Ratio for 2015. United States US: Incidence of Tuberculosis: per 100,000 People data is updated yearly, averaging 4.900 Ratio from Dec 2000 (Median) to 2016, with 17 observations. The data reached an all-time high of 6.700 Ratio in 2000 and a record low of 3.100 Ratio in 2016. United States US: Incidence of Tuberculosis: per 100,000 People data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Incidence of tuberculosis is the estimated number of new and relapse tuberculosis cases arising in a given year, expressed as the rate per 100,000 population. All forms of TB are included, including cases in people living with HIV. Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may differ from those published previously.; ; World Health Organization, Global Tuberculosis Report.; Weighted average;

In 2022, there were 565 reported deaths due to tuberculosis, a significant decrease from 5,217 deaths in 1970. This statistic depicts the number of deaths due to tuberculosis in the United States from 1960 to 2022. Tuberculosis Disease Of all infectious diseases, tuberculosis (TB) remains one of the most deadly worldwide. TB is a contagious lung disease caused by bacteria and passed through the air from an infected person to others. It often remains dormant for a few years before presenting as an active case in about five percent of latent cases. Common symptoms include coughing, including coughing up blood, and unexplained weight loss as the infection begins to spread throughout the body. Without antibiotic treatment, about one third of those with an active infection will die within two years and another third within five years. At-risk Populations Although the death rate for TB in the United States and other developed countries has remained relatively low over the past thirty years, other countries are more heavily burdened by this disease. The regions of Africa and South-East Asia have the highest number of tuberculosis deaths worldwide. In 2022, there were around 632 thousand deaths due to tuberculosis in South-East Asia, compared to just 35 thousand in the Americas.

In 2022, Haiti had the highest incidence of tuberculosis in Latin America and the Caribbean, with around *** new cases per 100,000 population reported that year. Meanwhile, Peru ranked second with *** new cases per 100,000 inhabitants that same year. In contrast, Antigua and Barbuda and Barbados registered the lowest tuberculosis incidence per 100,000 people in the region.

The average for 2022 based on 20 countries was 50.44 cases per 100,000 people. The highest value was in Haiti: 154 cases per 100,000 people and the lowest value was in Puerto Rico: 0.75 cases per 100,000 people. The indicator is available from 2000 to 2023. Below is a chart for all countries where data are available.

Download reports and data on tuberculosis incidences in Massachusetts, including a 5-year summary and demographic breakouts.

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that a loss of all U.S. funding to national TB programs, without replacement, would result in an additional 2.2 million deaths from tuberculosis from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 68.7 million additional MTB infections over this period. MTB infections are the primary cause of tuberculosis. This paper has not been peer-reviewed, so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in tuberculosis infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

In 2023, Guyana recorded an estimate of ** deaths per 100,000 people due to tuberculosis, which made it the country with the highest tuberculosis mortality rate in the Latin American and Caribbean region. Paru and Bolivia followed, with ** and ** tuberculosis deaths per 100,000 inhabitants, respectively. That year, Jamaica had the lowest tuberculosis death incidence in the region, with **** deceases per 100,000 people.

In 2023, Brazil was the Latin American country with the highest number of reported deaths due to tuberculosis in the region, with approximately ***** cases. Peru and Mexico followed that year, recording ***** and ***** tuberculosis deaths, while Bolivia's death toll due to this illness reached around ***** fatal cases.

The USA: Cases of Tuberculosis per 100,000 people: The latest value from 2023 is 3.1 cases per 100,000 people, an increase from 2.6 cases per 100,000 people in 2022. In comparison, the world average is 102.34 cases per 100,000 people, based on data from 193 countries. Historically, the average for the USA from 2000 to 2023 is 4.15 cases per 100,000 people. The minimum value, 2.3 cases per 100,000 people, was reached in 2020 while the maximum of 6.7 cases per 100,000 people was recorded in 2000.

This dataset contains estimates of morbidity rates for the major infections causes and elevated lead levels in blood among children, shared by the Big Cities Health Coalition members represented by the largest metropolitan health departments in the United States. The estimated values morbidity rates cover the 2010-2018 period and are described by sex and race/ethnicity.

United States US: Tuberculosis Case Detection Rate: All Forms data was reported at 87.000 % in 2016. This stayed constant from the previous number of 87.000 % for 2015. United States US: Tuberculosis Case Detection Rate: All Forms data is updated yearly, averaging 87.000 % from Dec 2000 (Median) to 2016, with 17 observations. The data reached an all-time high of 87.000 % in 2016 and a record low of 87.000 % in 2016. United States US: Tuberculosis Case Detection Rate: All Forms data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Tuberculosis case detection rate (all forms) is the number of new and relapse tuberculosis cases notified to WHO in a given year, divided by WHO's estimate of the number of incident tuberculosis cases for the same year, expressed as a percentage. Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may differ from those published previously.; ; World Health Organization, Global Tuberculosis Report.; Weighted average;

NNDSS - Table III. Tuberculosis - 2018.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying WONDER data. Data on United States will exclude counts from US territories.

Footnote: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum.

• Case counts for reporting year 2017 and 2018 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf

† Data for TB are displayed quarterly.

NNDSS - Table IV. Tuberculosis - 2015.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States will exclude counts from US territories. Footnote:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum. * Case counts for reporting year 2014 and 2015 are provisional through the end of the quarter, January 2, 2016. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf Data for TB are displayed quarterly.

United States US: Tuberculosis Treatment Success Rate: % of New Cases data was reported at 83.000 % in 2015. This records a decrease from the previous number of 85.000 % for 2014. United States US: Tuberculosis Treatment Success Rate: % of New Cases data is updated yearly, averaging 83.000 % from Dec 2000 (Median) to 2015, with 16 observations. The data reached an all-time high of 86.000 % in 2008 and a record low of 62.000 % in 2009. United States US: Tuberculosis Treatment Success Rate: % of New Cases data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Tuberculosis treatment success rate is the percentage of all new tuberculosis cases (or new and relapse cases for some countries) registered under a national tuberculosis control programme in a given year that successfully completed treatment, with or without bacteriological evidence of success ('cured' and 'treatment completed' respectively).; ; World Health Organization, Global Tuberculosis Report.; Weighted average;

Latent Tuberculosis Infection Diagnostics Market Outlook

As per our latest research, the global latent tuberculosis infection diagnostics market size reached USD 1.68 billion in 2024, and the market is poised to grow at a CAGR of 5.8% during the forecast period. By 2033, the market is projected to reach USD 2.82 billion, driven by increasing awareness, improved diagnostic technologies, and robust public health initiatives. The market’s expansion is underpinned by the rising burden of latent tuberculosis infection (LTBI) worldwide, especially in high-risk populations, and the concerted efforts of governments and international health organizations to curb the spread of tuberculosis.

One of the primary growth factors for the latent tuberculosis infection diagnostics market is the increasing prevalence of tuberculosis, particularly in developing countries. According to recent data from the World Health Organization, nearly a quarter of the global population is estimated to have latent TB infection, representing a significant reservoir for future active TB cases. This high prevalence has necessitated the scaling up of screening and diagnostic programs, especially in regions with high TB incidence. Additionally, the emergence of multidrug-resistant TB strains has further highlighted the importance of early detection and management of latent infections, as this can significantly reduce the risk of progression to active and transmissible disease. Investments in public health infrastructure and targeted awareness campaigns are further accelerating the adoption of advanced diagnostic solutions for LTBI.

Technological advancements in diagnostic methodologies are also fueling market growth. The development and commercialization of novel test types, such as Interferon Gamma Release Assays (IGRAs), have revolutionized the landscape of LTBI diagnostics. These tests offer higher specificity and sensitivity compared to the traditional Tuberculin Skin Test (TST), especially in populations vaccinated with Bacille Calmette-Guérin (BCG). The growing preference for blood-based assays, which require fewer patient visits and provide faster results, is driving adoption in both high- and low-resource settings. Furthermore, ongoing research into point-of-care diagnostics and digital health solutions is expected to enhance accessibility and efficiency, making it easier for healthcare providers to identify and manage LTBI cases effectively.

The regional outlook for the latent tuberculosis infection diagnostics market is characterized by significant disparities in disease burden and healthcare infrastructure. Asia Pacific leads the market in terms of volume, owing to its large population base and high TB prevalence, particularly in countries like India, China, and Indonesia. North America and Europe, while having lower overall TB incidence, are witnessing increased demand for LTBI diagnostics due to proactive screening programs among high-risk groups such as immigrants, healthcare workers, and immunocompromised individuals. Meanwhile, Latin America and the Middle East & Africa are gradually ramping up investments in diagnostic capabilities, supported by international funding and regional collaborations aimed at TB elimination.

Test Type Analysis

The test type segment in the latent tuberculosis infection diagnostics market is primarily divided into Tuberculin Skin Test (TST), Interferon Gamma Release Assays (IGRAs), and other emerging diagnostic methods. The Tuberculin Skin Test, which has been the cornerstone of LTBI diagnosis for decades, continues to hold a significant market share due to its low cost, simplicity, and widespread availability. However, the TST is often limited by its lower specificity, especially in BCG-vaccinated populations, and the requirement for multiple patient visits. Despite these limitations, TST remains the preferred choice in many low-resource settings, where cost and infrastructure constraints dictate diagnostic practices. The sustained use of TST is also supported by ongoing training programs and public health camp

The average for 2022 based on 12 countries was 55.42 cases per 100,000 people. The highest value was in Peru: 153 cases per 100,000 people and the lowest value was in Chile: 17 cases per 100,000 people. The indicator is available from 2000 to 2023. Below is a chart for all countries where data are available.

Tuberculosis Therapeutics Market Outlook

The global tuberculosis therapeutics market size was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. The significant growth in the market can be attributed to increased awareness about tuberculosis (TB), advancements in diagnostic technologies, and heightened government initiatives for TB eradication. Moreover, the rise in drug-resistant TB cases necessitates the development of new and effective therapeutic options, fuelling market growth.

The primary growth factor driving the tuberculosis therapeutics market is the alarming rise in the incidence of TB worldwide. According to the World Health Organization (WHO), TB is one of the top 10 causes of death globally, with millions of new cases reported annually. The WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030. This has led to increased funding and research initiatives to develop effective TB drugs and treatment protocols, thereby propelling market growth. Additionally, the emergence of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has intensified the need for novel therapeutics.

Another significant growth driver is the increasing government and non-governmental organization (NGO) interventions and funding for TB control programs. Governments across the globe are implementing national TB programs, supported by organizations like the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which provide substantial funding for TB diagnostics and treatments. These initiatives not only enhance the accessibility and affordability of TB therapeutics but also spur the demand for advanced drug formulations and combinations, contributing to market expansion. Furthermore, strategic collaborations between pharmaceutical companies and research institutions are fostering the development of innovative TB drugs.

Technological advancements in the field of diagnostics are also contributing to the growth of the tuberculosis therapeutics market. The introduction of rapid diagnostic tests, such as GeneXpert and TB-LAMP, has significantly improved the speed and accuracy of TB diagnosis, enabling timely initiation of treatment. Improved diagnostic capabilities help in identifying drug-resistant strains more efficiently, leading to better-targeted treatment regimens. Moreover, the integration of digital health technologies, such as mobile health (mHealth) applications, is enhancing patient adherence to TB treatment, thereby improving treatment outcomes and driving market growth.

The regional outlook for the tuberculosis therapeutics market indicates significant growth opportunities across various geographies. Asia Pacific holds the largest market share due to the high burden of TB in countries like India, China, and Indonesia. North America and Europe are also anticipated to witness substantial growth, driven by increased research funding and the presence of major pharmaceutical companies. The Middle East and Africa region, with its high TB prevalence rates, is expected to see growth supported by international aid and government initiatives. Latin America is projected to show moderate growth, with efforts to strengthen healthcare infrastructure and TB control programs.

Drug Class Analysis

The tuberculosis therapeutics market is segmented by drug class into first-line drugs, second-line drugs, and combination drugs. First-line drugs, including isoniazid, rifampicin, ethambutol, and pyrazinamide, have been the cornerstone of TB treatment for decades. These drugs are highly effective against Mycobacterium tuberculosis and are recommended for treating drug-susceptible TB. Despite their efficacy, the emergence of drug-resistant TB strains has posed significant challenges, leading to increased focus on second-line and combination drugs. First-line drugs continue to dominate the market due to their widespread use and cost-effectiveness, especially in high-burden regions.

Second-line drugs, such as fluoroquinolones and injectable agents like amikacin, are used to treat MDR-TB and XDR-TB cases. The demand for second-line drugs is rising due to the growing incidence of drug-resistant TB, which cannot be effectively treated with first-line drugs. These drugs are often more expensive and have more severe side effects, but they are crucial for managing res

Background: Drug-resistant tuberculosis (DR-TB), especially multidrug-resistant tuberculosis (MDR-TB) is a public health threat. Little is known about estimates of different profiles and rates of DR-TB among children globally.Methods: We did a systematic review and meta-analysis of observational studies reporting DR-TB among children by searching Embase, PubMed, and Scopus databases from January 1, 2000 to October 1, 2020. Publications reporting more than 60 children with bacteriological confirmed tuberculosis and phenotypical drug susceptibility testing (DST) results were included. Pooled proportions of MDR-TB and sub-analysis by age subgroups, regions, economical levels were performed.Results: We identified 4,063 studies, of which 37 were included. Of 23,652 pediatric TB patients, the proportions of DR-TB, MDR-TB, mono-resistant TB, polydrug resistant TB, extensively drug-resistant TB were 13.59% (1,964/14,453), 3.72% (881/23,652), 6.07% (529/8,719), 1.61% (119/7,361), 0.44% (30/6,763), respectively. The pooled proportion of MDR-TB among 23,652 children of 37 studies was 3.7% (95% CI, 3.5–4.0%). Rate of MDR-TB was much lower in high-income countries (1.8%) than that in lower-middle-income countries (6.3%) and upper-middle-income countries (7.3%). More specifically, the rates of MDR-TB were 1.7% in USA, 1.7% in UK, 2.9% in India, 6.0% in South Africa, 9.8% in China, respectively.Conclusions: The burden of DR-TB remains high in children, and there are potential associations between rates of pediatric MDR-TB and national economical levels. More interventions on child TB cases in low-income countries may be urgently needed in future.

IntroductionThe Centers for Disease Control and Prevention is considering implementation of overseas medical screening of student-visa applicants to reduce the numbers of active tuberculosis cases entering the United States.ObjectiveTo evaluate the costs, cases averted, and cost-effectiveness of screening for, and treating, tuberculosis in United States-bound students from countries with varying tuberculosis prevalence.MethodsCosts and benefits were evaluated from two perspectives, combined and United States only. The combined perspective totaled overseas and United States costs and benefits from a societal perspective. The United States only perspective was a domestic measure of costs and benefits. A decision tree was developed to determine the cost-effectiveness of tuberculosis screening and treatment from the combined perspective.ResultsFrom the United States only perspective, overseas screening programs of Chinese and Indian students would prevent the importation of 157 tuberculosis cases annually, and result in $2.7 million in savings. From the combined perspective, screening programs for Chinese students would cost more than $2.8 million annually and screening programs for Indian students nearly $440,000 annually. From the combined perspective, the incremental cost for each tuberculosis case averted by screening Chinese and Indian students was $22,187 and $15,063, respectively. Implementing screening programs for German students would prevent no cases in most years, and would result in increased costs both overseas and in the United States. The domestic costs would occur because public health departments would need to follow up on students identified overseas as having an elevated risk of tuberculosis.ConclusionsTuberculosis screening and treatment programs for students seeking long term visas to attend United States schools would reduce the number of tuberculosis cases imported. Implementing screening in high-incidence countries could save the United States millions of dollars annually; however there would be increased costs incurred overseas for students and their families.